Outlook Therapeutics Inc (OTLK) FinancialsOTLKOutlook Therapeutics Inc

Evaluating the bottom line, Outlook Therapeutics Inc maintains a gross margin of -95.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -124255.28%, while the net margin is -233554.85%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively OTLK converts its operational activities into shareholder value.

In the context of the broader market, OTLK competes directly with industry leaders such as TNYA and NRXP. With a market capitalization of $157.56M, it holds a significant position in the sector. When comparing efficiency, OTLK's gross margin of -95.00% stands against TNYA's 100.00% and NRXP's 35.02%. Such benchmarking helps identify whether Outlook Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $20.3 million in Q3 2026, with a gross margin of -95% in Q3 2026, indicating severe financial challenges. The forward P/E ratio is 2.8498, suggesting potential for future earnings but reflecting current struggles.